As I followed my Pca story, I have now changed focus from straight genomic mutations [AR mutations,etc] to what I see as a new focus on how Pca treatments induce senescence and how this senescence is a double edged sword. The following clinical article is a newer view:
file:///Users/podsart/Downloads/fimmu-15-1395047.pdf
The above figure is from this article [couldnt get the second figure to be added, it keeps replacing the first??]
From a previous thread on this subject, I got the sense that our Pca treatments first can effect aptosis and actually kill the Pca cell and then the treatment tends to produce these senescense cells that have a good and bad side, as shown above and described in the article [hopefully the above link works.
In my case, I am trying to ascertain the optimal strategy, given I have already progressed on 2 sequential AR monotherapies [xtandi then erleada]. They have just started me on relugolix ADT. My PSA is now very low after just emerging from undetectable, I am sure it has acquired a more aggressive nature and can therefore progress rapidly from here, so in my view, the current low PSA is temporary. Also, I am sure I already have a lot of senescence cells.
Given the above, does it make sense for me to add another systemic therapy such as chemo [which I never had], perhaps inducing more scenescense, with the above associated good/bad duality? What about Provenge, which the article doesnt address? Does Provenge also induce senescence?
How do you chose and optimal strategy. Would appreciate your views.
Suggestions on next step of therapy
